• Equity PC Ratio   0.57
  • |
  • Index PC Ratio   1.14
  • |
  • Total PC Ratio   0.97
  • |
  • VIX PC Ratio   0.54
  • VIX 12.09
  • VXN 15.15
  • VXO 12.04
  • ISEE 85.00

TruCharts Trading Strategies and Stock Buy/Sell Reports
(Show Details)

Chart Settings
No saved settings found!

Chart Type:
From: / / To: / /
Show detail in :
 Chart Skins:      
Price Overlays:

Indicator Windows:

ARWR (Arrowhead Pharmaceuticals Inc.)
Last Trade 18.17 Dividend/Share 0 PE Ratio -51.91
Date April 18-2019 Dividend Yield 0.000 Return on Assets -13.61
Change -0.21 ExDividend Date 0 Return on Capital null
Bid null Latest EPS -0.66 Price/Sale 37.125
Ask null LatestEPS Date 2018-09-30 Price to Book 9.95
Volume null EPS ttm -0.350 Institutional % 97.3
Avg Volume 1.38M Shares Outstanding 94.21M Insider % 5.7
Open 18.32 Float 89.23M Short Ratio null
Prev Close 18.38 Return On Equity -24.06 5 Year Change % 0.383
High 18.57 Consensus EPS 0.76 2 Year Change % 10.954
Low 17.5 No. of Estimate 4.000 1 Year Change % 1.653
52 Week High 22.39 EPS Surprise $ null YTD Change % 0.385
52 Week Low 6.3066 EPS Surprise Percent -82.8947 6 Month Change % 0.400
52 Week Change 159.201 EBITDA 0M 3 Month Change % 0.387
50 Day MA 18.5038 Revenue 0M 1 Month Change % -0.047
200 Day MA Gross Profit 0M 5 Day Change % -0.008
Market Cap 1711.75M Cash 0M 30 Day Change % -0.013
Beta 2.179543 Debt 0M Stock Exchange Nasdaq Global Select
Sector Healthcare Revenue Per Share 0 Short Interest 0
Short Date 0 Revenue Per Employee 0 Short Ratio null
Data courtesy of IEX
Company Profile

Arrowhead Research Corporation, through its subsidiaries, identifies advances in nanotechnology and matches them with product development opportunities in high-growth markets, focusing on the electronics and biotech industries. It focuses on developing, commercializing, and licensing a range of nanotechnology products and applications, including anti-cancer drugs, RNAi therapeutics, regenerative therapeutics, advanced drug delivery technology, energy storage technology, carbon-based electronics, and fullerene anti-oxidants. The company has developed Cyclosert, a proprietary drug delivery platform technology based on a nano-engineered class of linear cyclodextrin-containing polymers. Its lead anti-cancer drug candidate IT-101 is a combination of Cyclosert and the potent anti-cancer drug, camptothecin, is under Phase I clinical trials. Arrowhead Research also focuses on the design, development, and commercialization of novel RNA interference (RNAi) therapeutics to treat diseases and other medical conditions by combining RNAi therapeutics with patented and proprietary delivery technologies. Its CALAA-01 product is a formulation of proprietary delivery technology with a siRNA duplex targeting the M2 subunit of ribonucleotide reductase. In addition, the company engages in the manufacture and application of carbon nanotubes-based products for the electronics industry. The company, formerly known as InterActive Group, Inc., was founded in 2003 and is headquartered in Pasadena, California.